JPMorgan on Definium Therapeutics (DFTX.US): A Worthwhile Investment in Neuropsychiatry—Initiating at Overweight
Summaries are public. PDF access requires an active membership; all members have the same access. Sign in
JPMorgan initiates coverage of Definium Therapeutics (DFTX) with an Overweight rating and an $84 price target, based on DCF and sum-of-the-parts analysis. The core asset, DT120 ODT—a D-tartrate formulation of LSD—shows transformative potential in major depressive disorder (MDD) and generalized anxiety disorder (GAD), with a launch anticipated in 2028. The firm views the asset as de-risked, supported by a dense clinical milestone calendar. In GAD, the 2b trial demonstrated a clear dose-response, with the 100µg and 200µg arms achieving statistical significance at both week 4 and week 8. In MDD, the Phase 3 Emerge study met its primary endpoint, showing statistically significant improvement from baseline in MADRS total score at week 6. The ODT formulation offers faster onset and higher bioavailability than the capsule version. Upcoming catalysts include a pre-NDA meeting for DT120 ODT in Q4 2026, NDA submission in H1 2027, Ascend Phase 3 topline data in MDD and the start of the PTSD Haven trial in 2027, plus initial Phase 2 data for DT402 (R(-)-MDMA) in autism spectrum disorder in Q4 2026. JPMorgan projects DT120 ODT sales approaching $5 billion by 2035, citing first-mover advantage and a favorable regulatory environment in neuropsychiatry.
Key exhibits
Exhibit 1
Exhibit 2
Exhibit 3
Exhibit 4
Exhibit 5
Exhibit 6
Exhibit 7
